Revenue
2.79 million USD
2023 Q3 · USD
Exact inputs and evidence
- Revenue: 2789993 USD Source
Market value is not computed: no listed ticker is recorded for this company.
18 filing records in this dataset, filed from 2020-06-15 to 2023-11-13. Reported financial figures are available; chart coverage varies by period.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.
This issuer has insider filings in the store, but no transaction in this window or code group.
2.79 million USD
2023 Q3 · USD
-1,061.87%
2023 Q3 · %
-28.1 million USD
2023 Q3 · USD
-34.5 million USD
2023 Q3 · USD
21607412 USD
105765954 shares
1.64% · 1.71 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
96.6 million USD
2022-10-01 – 2023-09-30
112 million USD
2022-10-01 – 2023-09-30
19.3 million USD
2022-10-01 – 2023-09-30
92.7 million USD
2022-10-01 – 2023-09-30
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2023-11-13.
Financial data available through: 2022-12-31.
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Prior period
USD 0
–
Current period
USD 226.58 million
–
226579563 − 0 = 226579563 USD
0 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source226579563 USD · 2022-01-01 – 2022-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
−USD 45.9 million
–
Current period
USD 98.29 million
–
98293213 − -45902481 = 144195694 USD
-45902481 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source98293213 USD · 2022-01-01 – 2022-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
−USD 44.7 million
–
Current period
USD 183.52 million
–
183518622 − -44698758 = 228217380 USD
-44698758 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source183518622 USD · 2022-01-01 – 2022-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
USD 8.8 million
–
Current period
USD 12.77 million
–
12766522 − 8802182 = 3964340 USD
8802182 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source12766522 USD · 2022-01-01 – 2022-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2021 2021-01-01 – 2021-12-31 | 0 | 45511830 Derived | -45511830 | 390651 Derived | -45902481 | -53500940 Derived | Source
|
| 2022 2022-01-01 – 2022-12-31 | 226579563 | 101057268 Derived | 125522295 | 27229082 Derived | 98293213 | 170752100 Derived | Source
|
Amounts are exact, in USD.
Sales over time and how quickly they are changing.
Revenue reported for each complete financial period.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2021 | Revenue | 0 |
|
| 2022 | Revenue | 226579563 |
|
Change in revenue from the same financial period one year earlier.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2021 | Year over year | No prior comparable period |
|
| 2022 | Year over year | No prior comparable period |
|
How much revenue becomes profit, and how much cash operations generate.
Operating income, net income and free cash flow as a share of revenue.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2021 | Operating margin | Not reported |
|
| 2022 | Operating margin | 55.4% |
|
| 2021 | Net margin | Not reported |
|
| 2022 | Net margin | 43.4% |
|
| 2021 | Free cash flow margin | Not reported |
|
| 2022 | Free cash flow margin | 75.4% |
|
Cash generated by the company’s normal business operations.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2021 | Operating cash flow | -44698758 |
|
| 2022 | Operating cash flow | 183518622 |
|
Operating cash flow minus capital expenditure for the same period and unit.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2021 | Free cash flow | -53500940 |
|
| 2022 | Free cash flow | 170752100 |
|
Liabilities and short-term ability to meet obligations at each period end.
Total liabilities as a share of total assets.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2021 | Liabilities / assets | 3.1% |
|
| 2022 | Liabilities / assets | 15.8% |
|
Current assets divided by current liabilities.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2021 | Current assets / current liabilities | 30.56× |
|
| 2022 | Current assets / current liabilities | 6.66× |
|
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2020 2020-01-01 – 2020-12-31 | −USD 13.37 million Exact valueExact value: -13373003 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 8.3 million Exact valueExact value: -8302856 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 9.8 million Exact valueExact value: 9797400 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 18.1 million Calculation and evidence-8302856 − 9797400 USD Exact free cash flow: -18100256 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2021 2021-01-01 – 2021-12-31 | −USD 45.9 million Exact valueExact value: -45902481 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 44.7 million Exact valueExact value: -44698758 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 8.8 million Exact valueExact value: 8802182 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 53.5 million Calculation and evidence-44698758 − 8802182 USD Exact free cash flow: -53500940 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2022 2022-01-01 – 2022-12-31 | USD 98.29 million Exact valueExact value: 98293213 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 183.52 million Exact valueExact value: 183518622 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 12.77 million Exact valueExact value: 12766522 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 170.75 million Calculation and evidence183518622 − 12766522 USD Exact free cash flow: 170752100 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
18 filings · 965 latest values · 965 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001811764, 1811764, PNT, RACA, edgar:1811764, txac
Also known as POINT BIOPHARMA GLOBAL INC., POINT Biopharma Global Inc, POINT Biopharma Global Inc., Therapeutics Acquisition Corp.